by Gemma Escarré,
Aelix Therapeutics, a CataloniaBio & HealthTech member, and Gilead Sciences Inc. have entered into collaboration to jointly evaluate proprietary research products in a strategic clinical study aimed at achieving a functional cure for HIV.
The collaboration will allow them to conduct clinical study Aelix-003 to assess the safety, tolerability, immunogenicity and efficacy of a regimen of the Aelix HTI T-cell vaccine and the Gilead Toll-Like Receptor 7 agonist vesatolimod in HIV-infected individuals already on antiretroviral therapy. The Aelix-003 trial is expected to begin in early 2019.
Aelix Therapeutics has its headquarters at the Barcelona Science Park.
Photo: Dr Ian McGowan, Aelix VP for Medical Affairs - © Aelix Therapeutics